Inside the research
Vir Biotechnology, Inc.
VIR Research profile · latest available data
Price overview
$10.66
▼ -0.06 (-0.6%)
| 52w hi | $11.63 |
|---|---|
| 52w lo | $5.12 |
| Vol | 1.13M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.31
| Short | +0.41 |
|---|---|
| Medium | +0.40 |
| Long | -0.09 |
computed 2026-09-27
Key fundamentals
Vir Biotechnology, Inc.
Healthcare · Biotechnology
| Market cap | $1.80B |
|---|---|
| Enterprise value | $1.36B |
| Forward P/E | -4.29x |
| EV / EBITDA | -5.09x |
| P / S (ttm) | 5.95x |
| Profit margin | -83.0% |
| Return on equity | -26.1% |
| Revenue growth | +19582.5% |
| Debt / equity | 9.49 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.05 | |
| Sector | +0.08 | |
| Technical | +0.29 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Risk Metrics
| Beta vs SPX | 1.58 |
|---|---|
| Corr SPX | 0.32 |
| Annual vol | 78.5% |
| Annual ret | +43.9% |
| Sharpe | 0.56 |
| Max DD | -65.7% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-07-24 | Officer / Director Change | read |
| 2026-06-10 | Officer / Director Change | read |
| 2026-05-28 | Officer / Director Change, Shareholder Vote | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-04-10 | Officer / Director Change | read |
| 2026-03-04 | Officer / Director Change | read |
| 2026-03-02 | Other Material Event | read |
| 2026-02-26 | Material Agreement, Exhibits | read |
| 2026-02-23 | Material Agreement, Earnings Release… | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2025-12-16 | Material Agreement, Other Material Event… | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 96.7% |
| HHI | 4,505 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $101.53M | 9.96M |
| Fidelity / FMR LLC | $23.62M | 2.32M |
| Citadel Advisors | $10.64M | 1.04M |
| Renaissance Technologies | $10.36M | 1.02M |
| AQR Capital Management | $5.92M | 581.42K |
| Capital Research / Capital World | $4.70M | 461.33K |
| Millennium Management | $489.05K | 47.99K |
| T. Rowe Price Group | $1.32K | 129.79K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2019–2025 · 7 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $68.56M | +77.1% | |
| Operating income | -$479.33M | +98.0% | |
| Net income | -$615.06M | +0.0% | |
| Cash from ops | -$778.78M | — |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $10.82 | $10.82 | $10.48 | $10.66 | 1.13M |
| Sep 24 | $11.02 | $11.15 | $10.35 | $10.72 | 2.09M |
| Sep 23 | $11.44 | $11.53 | $10.85 | $11.09 | 1.68M |
| Sep 22 | $10.99 | $11.72 | $10.89 | $11.50 | 1.85M |
| Sep 21 | $10.77 | $10.94 | $10.66 | $10.88 | 1.45M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →